A patient with three different autoimmune diseases has entered complete remission after undergoing an experimental treatment that effectively reset her immune system. The 47-year-old woman in Germany ... Morning Overview on MSN: CAR-T therapy sends 3 autoimmune diseases into remission in 1 patient A woman in her thirties who was dependent on blood transfusions and unresponsive to every standard treatment for her three overlapping autoimmune diseases is now symptom-free and off all medications ...
CAR-T cell therapy puts woman's three autoimmune diseases into remission after single infusion when nine previous treatments failed over a decade. The Times of India on MSN: Autoimmune diseases may start in the gut: Early signs your immune system is turning against you and what you can do to restore balance Autoimmune diseases may start in the gut: Early signs your immune system is turning against you and what you can do to restore balance Fierce Biotech: In a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patient A CAR-T cell therapy has successfully treated not one, not two, but three different autoimmune diseases at once in a patient, providing further proof of the modality’s promise in the disease area as a ... In a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patient CAR-T cell therapy, originally developed for cancer, is showing ever more promise as a treatment for autoimmune diseases. A tick protein that inhibits multiple immune signals could lead to better treatments for autoimmune diseases and inflammation.
autoimmune, Nature: One woman, three autoimmune diseases: CAR-T therapy vanquishes ultra-rare disease trio Healio: FDA to ‘carefully shepherd’ CAR T-cell therapy trials in autoimmune, rheumatic disease The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen receptor T-cell therapies in autoimmune and rheumatic diseases.“It is quite ... FDA to ‘carefully shepherd’ CAR T-cell therapy trials in autoimmune, rheumatic disease Royalty Pharma has made another play in the autoimmune space, this time crowning Johnson & Johnson as the beneficiary. Royalty and J&J have agreed to co-fund the development of a chronic autoimmune ... New data shows how autoimmune disease is quietly limiting women’s careers. Here's what employers can do about it.
